Valneva is advancing toward U.S. FDA accelerated approval of the France-based biologics company’s VLA1553 after the specialty vaccine was shown to be safe and effective against mosquito-transmitted chikungunya disease, in a published analysis of Phase III results.
Moderna plots vaccines against 15 pathogens with future pandemic potential
Business, Chikungunya virus, Coronavirus Disease (COVID-19) Pandemic, Crimean-Congo hemorrhagic fever (CCHF), Dengue Fever, Ebola, HIV Vaccines, Kenya, Low-Income Countries, Malaria, Marburg Virus, MERS, Middle-Income Countries, Moderna, Mosquito-Borne Infections, National Institutes of Health, Pandemics, Patents, Pathogens, R&D, Vaccines, Viral InfectionsModerna Inc. plans to develop and begin testing vaccines targeting 15 of the world’s most worrisome pathogens by 2025 and will permanently waive the company’s COVID-19 vaccine patents for shots intended for certain low-income and middle-income countries.
An outbreak of dengue fever is suspected of killing dozens of people in India’s northern state of Uttar Pradesh since the start of September, and authorities launched a campaign to destroy mosquito breeding grounds.
French specialty vaccine maker Valneva shared positive topline results from ongoing trials for a potential single-shot vaccine against chikungunya.
Valneva SE was awarded Breakthrough Therapy Designation for the company’s single-shot chikungunya vaccine candidate, VLA1553, by the U.S. Food and Drug Administration.
After months of bad news regarding Covid-19 vaccine manufacturing issues, Emergent BioSolutions posted positive two-year data related to the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate.
Takeda has touted the potential of the company’s Dengue vaccine for several years, and new long-term data reinforces the promise of the medication that could prevent the deadly mosquito-borne virus.
Genetically modified mosquitoes were released for the first time in the United States, taking flight in the Florida Keys in a pilot program intended to reduce the spread of deadly diseases such as dengue, yellow fever and the Zika virus.
A new study that analyzed the coronavirus outbreak in Brazil found a link between the spread of the virus and past outbreaks of dengue fever that suggests exposure to the mosquito-transmitted illness may provide some level of immunity against Covid-19.
Takeda Pharmaceutical Co.’s experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but TAK-003 failed to protect against one type of the virus in people with no prior exposure to dengue.